The Supreme Court is leaving in place a $2 billion verdict in favor of women who claim they developed ovarian cancer from using Johnson & Johnson talc products.
The justices did not comment Tuesday in rejecting Johnson & Johnson's appeal. The company argued that it was not treated fairly in facing one trial involving 22 cancer sufferers who came from 12 states and different backgrounds.
A Missouri jury initially awarded the women $4.7 billion, but a state appeals court dropped two women from the suit and reduced the award to $2 billion. The jury found that the company’s talc products contain asbestos and asbestos-laced talc can cause ovarian cancer. The company disputes both points.
Johnson & Johnson, which is based in New Brunswick, New Jersey, has stopped selling its iconic talc-based Johnson’s Baby Powder in the U.S. and Canada, though it remains on the market elsewhere.
Justices Samuel Alito and Brett Kavanaugh took no part in the court's action. Alito owns $15,000 to $50,000 in Johnson & Johnson stock. Kavanaugh's father headed the trade association that lobbied against labeling talc a carcinogen and including a warning label on talc products.
Ethicists contacted by The Associated Press said they did not think E. Edward Kavanaugh's role required his son to step aside from the case.
Skift airline reporter Meghna Maharishi breaks down how the government shutdown is hitting air traffic control—and what it means for travelers and flight safety
Aya Kantorovich, Co-CEO of August Digital, breaks down Bitcoin’s surge, crypto ETFs, institutional investment trends, and the future of safer crypto access.
Most members of the Federal Reserve’s interest-rate setting committee supported further reductions to its key interest rate this year, minutes from last month’s meeting showed.
Sinead O’Sullivan breaks down Taylor Swift’s genius marketing for The Life of a Showgirl, which just set the record for most albums sold in a single week.
Markets are emerging from a turbulent Q3. Horizon’s Mike Dickson shares insights on interest rates, small caps, and where investors should look in Q4 and beyond
